The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102): Updated results of cohort G from a phase I/IIa study.
 
Jifang Gong
No Relationships to Disclose
 
Dan Liu
No Relationships to Disclose
 
Zengqing Guo
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Weijian Guo
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Chuan Qi
Employment - Transcenta
Stock and Other Ownership Interests - Transcenta
 
Lijuan Zhang
Employment - Transcenta
Stock and Other Ownership Interests - Transcenta
 
Zhenzhong Xia
Employment - Ascentage Pharma Group; Transcenta
 
Jianming Wang
Employment - Transcenta Therapeutics, Inc.
Stock and Other Ownership Interests - Transcenta Therapeutics, Inc.
 
Li Xu
Employment - Transcenta Therapeutics, Inc.
Stock and Other Ownership Interests - Transcenta Therapeutics, Inc.
 
Caroline Germa
Employment - Transcenta Therapeutics, Inc.
Stock and Other Ownership Interests - Transcenta Therapeutics, Inc.
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)